Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

AZD0486 seems highly active, including in patients relapsed on Car-T therapy.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.